Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Life Setting
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 54
- Registration Number
- NCT02199288
A Phase 1 Study of RO6806127 in Healthy Male Volunteers
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 37
- Registration Number
- NCT02196636
A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT02194166
- Locations
- 🇧🇾
State Inst N.N. Alexandrov Republican Scientific & Practical Centre of Oncology & Medical Radiology, A/g Lesnoy, Minsk Region, Belarus
🇰🇿Oncology centre of Astana; Chemotherapy department, Astana, Kazakhstan
🇧🇾Healthcare Institution "Brest Regional Oncologic Dispensary", Brest, Belarus
Comparative Bioavailability Study of Film-coated Tablet and Granule Formulations of RG1662
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RG1662 tabletDrug: RG1662 granules
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT02194244
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 163
- Registration Number
- NCT02187861
- Locations
- 🇦🇺
Royal Prince Alfred Hospital; Medical Oncology, Camperdown, New South Wales, Australia
🇧🇪Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇧🇪ZNA Stuivenberg, Antwerpen, Belgium
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants
- Conditions
- Alzheimer's Disease, Healthy Volunteer
- Interventions
- Drug: [11C]RO6924963Drug: [11C]RO6931643Drug: [18F]RO6958948
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT02187627
- Locations
- 🇺🇸
Johns Hopkins Universtiy; Radiology Dept, Baltimore, Maryland, United States
🇺🇸Parexel International; Harbor Hospital Center, Baltimore, Maryland, United States
A Single-center Study to Investigate How Quickly and to What Extent a Radioactive Dose of RO5285119 is Absorbed, Metabolized and Eliminated From the Body of Healthy Male Volunteers
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT02179866
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Solid Cancers
- Interventions
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 158
- Registration Number
- NCT02174172
- Locations
- 🇺🇸
HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 358
- Registration Number
- NCT02171429
- Locations
- 🇧🇬
Medical center Medconsult Pleven OOD, Pleven, Bulgaria
🇦🇷Centro de Investigaciones Medicas Mar Del Plata, Mar del Plata, Argentina
🇧🇬DCC Sv. Pantaleymon OOD, Pleven, Bulgaria
A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT02168530